Compare Wockhardt with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs GSK PHARMA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT GSK PHARMA WOCKHARDT/
GSK PHARMA
 
P/E (TTM) x -13.6 31.8 - View Chart
P/BV x 1.1 12.7 8.4% View Chart
Dividend Yield % 0.0 1.2 0.3%  

Financials

 WOCKHARDT   GSK PHARMA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
GSK PHARMA
Mar-19
WOCKHARDT/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0123,595 28.2%   
Low Rs5321,253 42.4%   
Sales per share (Unadj.) Rs355.9184.7 192.7%  
Earnings per share (Unadj.) Rs-60.326.3 -229.3%  
Cash flow per share (Unadj.) Rs-46.829.2 -160.4%  
Dividends per share (Unadj.) Rs0.0120.00 0.1%  
Dividend yield (eoy) %00.8 0.2%  
Book value per share (Unadj.) Rs257.8126.3 204.1%  
Shares outstanding (eoy) m110.63169.40 65.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.213.1 16.5%   
Avg P/E ratio x-12.892.2 -13.9%  
P/CF ratio (eoy) x-16.583.1 -19.9%  
Price / Book Value ratio x3.019.2 15.6%  
Dividend payout %076.1 -0.0%   
Avg Mkt Cap Rs m85,379410,626 20.8%   
No. of employees `0006.35.0 126.1%   
Total wages/salary Rs m9,3715,372 174.4%   
Avg. sales/employee Rs Th6,295.06,306.7 99.8%   
Avg. wages/employee Rs Th1,498.31,083.1 138.3%   
Avg. net profit/employee Rs Th-1,066.3898.0 -118.7%   
INCOME DATA
Net Sales Rs m39,36931,281 125.9%  
Other income Rs m1,2021,023 117.5%   
Total revenues Rs m40,57132,304 125.6%   
Gross profit Rs m186,009 0.3%  
Depreciation Rs m1,495486 307.7%   
Interest Rs m2,5556 42,581.7%   
Profit before tax Rs m-2,8306,540 -43.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582287 -1,248.0%   
Tax Rs m2572,373 10.8%   
Profit after tax Rs m-6,6694,454 -149.7%  
Gross profit margin %019.2 0.2%  
Effective tax rate %-9.136.3 -25.0%   
Net profit margin %-16.914.2 -119.0%  
BALANCE SHEET DATA
Current assets Rs m33,79620,061 168.5%   
Current liabilities Rs m26,91714,543 185.1%   
Net working cap to sales %17.517.6 99.0%  
Current ratio x1.31.4 91.0%  
Inventory Days Days7957 139.8%  
Debtors Days Days8914 634.6%  
Net fixed assets Rs m39,66414,343 276.5%   
Share capital Rs m5531,694 32.7%   
"Free" reserves Rs m27,96819,704 141.9%   
Net worth Rs m28,52221,398 133.3%   
Long term debt Rs m21,7312 1,086,555.0%   
Total assets Rs m81,62039,113 208.7%  
Interest coverage x-0.11,091.0 -0.0%   
Debt to equity ratio x0.80 815,189.2%  
Sales to assets ratio x0.50.8 60.3%   
Return on assets %-5.011.4 -44.2%  
Return on equity %-23.420.8 -112.3%  
Return on capital %-7.731.9 -24.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,807534 1,836.5%   
Fx outflow Rs m1,7897,091 25.2%   
Net fx Rs m8,019-6,557 -122.3%   
CASH FLOW
From Operations Rs m6843,994 17.1%  
From Investments Rs m6,302-1,433 -439.7%  
From Financial Activity Rs m-7,695-3,584 214.7%  
Net Cashflow Rs m-664-1,023 64.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 2.3 10.2 22.5%  
FIIs % 7.7 23.8 32.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 15.4 100.0%  
Shareholders   67,757 102,036 66.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare WOCKHARDT With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Moody's Economic Growth Forecast, Rising Retail Inflation, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their day on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 170 points (up 0.4%).

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Nov 14, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - SUVEN LIFESCIENCES COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS